- Home
- SOPH
SOPH
SOPHiA GENETICS SA
as of 10-01-2026 3:45pm EST
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 462.3M | IPO Year: | 2021 |
| Target Price: | $9.75 | AVG Volume (30 days): | 566.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $3.75 - $8.98 | Next Earning Date: | 11-03-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 23.24% | Revenue Growth (next year): | 24.63% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Stock Insider Trading Activity of SOPHiA GENETICS SA (SOPH)
Chief Executive Officer
Avg Cost/Share
$8.33
Shares
422
Total Value
$3,515.26
Owned After
670,229
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$8.33
Shares
774
Total Value
$6,447.42
Owned After
308,318
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$7.88
Shares
5,000
Total Value
$39,416.50
Owned After
208,387
SEC Form 4
Chief Legal Officer
Avg Cost/Share
$7.63
Shares
6,168
Total Value
$47,088.98
Owned After
338,884
SEC Form 4
Executive Chairman
Avg Cost/Share
$7.66
Shares
8,500
Total Value
$65,120.20
Owned After
3,435,822
SEC Form 4
Director
Avg Cost/Share
$8.13
Shares
6,250
Total Value
$50,817.50
Owned After
96,992
SEC Form 4
Director
Avg Cost/Share
$8.68
Shares
6,250
Total Value
$54,233.13
Owned After
96,992
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$8.68
Shares
5,000
Total Value
$43,396.50
Owned After
208,387
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Muken Ross | SOPH | Chief Executive Officer | Sep 21, 2026 | Sell | $8.33 | 422 | $3,515.26 | 670,229 | |
| CARDOZA GEORGE | SOPH | Chief Financial Officer | Sep 21, 2026 | Sell | $8.33 | 774 | $6,447.42 | 308,318 | |
| Menu Philippe | SOPH | Chief Medical Officer | Sep 14, 2026 | Sell | $7.88 | 5,000 | $39,416.50 | 208,387 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Sep 14, 2026 | Sell | $7.88 | 4,000 | $31,537.60 | 552,887 | |
| Van Well Daan | SOPH | Chief Legal Officer | Sep 11, 2026 | Sell | $7.63 | 6,168 | $47,088.98 | 338,884 | |
| Camblong Jurgi | SOPH | Executive Chairman | Sep 10, 2026 | Sell | $7.66 | 8,500 | $65,120.20 | 3,435,822 | |
| HIBBS KATHY L | SOPH | Director | Sep 8, 2026 | Sell | $8.13 | 6,250 | $50,817.50 | 96,992 | |
| Xu Zhenyu | SOPH | Chief Scientific Officer | Aug 27, 2026 | Sell | $8.91 | 10,000 | $89,096.00 | 552,887 | |
| HIBBS KATHY L | SOPH | Director | Aug 25, 2026 | Sell | $8.68 | 6,250 | $54,233.13 | 96,992 | |
| Menu Philippe | SOPH | Chief Medical Officer | Aug 25, 2026 | Sell | $8.68 | 5,000 | $43,396.50 | 208,387 |
Compare SOPH vs Leading Stocks
See how SOPH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SOPH SOPHiA GENETICS SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.